Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 3/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | TNK2 | Q07912 | 12/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | TEC | P42680 | 1/20 | 0.31 |
| ▸ | TXK | P42681 | 1/20 | 0.31 |
| ▸ | BMX | P51813 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.31 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.31 |
| ▸ | RAF1 | P04049 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19280361 | 0.81 | RET (0.41) | RETKDRTNK2BTK | |
| SCHEMBL12283330 | 0.79 | CSNK2A2 (0.43) | FGFR1CSNK2A2CSNK2A1FGFR3 | |
| SCHEMBL19280424 | 0.78 | NAPRT (0.42) | TNK2BTK | |
| SCHEMBL19280151 | 0.72 | TNK2 (0.30) | TNK2 | |
| SCHEMBL19711100 | 0.71 | FGFR1 (0.31) | TNK2FGFR1FGFR2FGFR3 | |
| SCHEMBL1478690 | 0.70 | KMT2A (0.41) | — | |
| SCHEMBL23370638 | 0.69 | SRC (0.34) | SRCRETKDRTNK2FGFR1 | |
| Hydrochloric Acid SCHEMBL1516575 | 0.69 | KMT2A (0.40) | — | |
| SCHEMBL21198893 | 0.68 | AURKB (0.48) | KDRFGFR1CSNK2A2CSNK2A1 | |
| SCHEMBL13869068 | 0.68 | SLC6A3 (0.32) | CSNK2A2CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3209664-B1 | BICYCLIC HETEROARYL AMINE COMPOUNDS AS PI3K INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-3209664-B1 | BICYCLIC HETEROARYL AMINE COMPOUNDS AS PI3K INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-06-03 | — | — | EP | disclosed |
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| EP-3209664-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS AS PI3K INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | PIK3R3, JAK2, JAK3 | SRC 163/4885RET 332/4885KDR 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.